$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022047638 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.944M	$2.630M	$2.463M
YoY Change	-18.03%	26.17%	-11.73%
% of Gross Profit
Research & Development	$1.244M	$1.200M	$596.3K
YoY Change	-26.49%	-48.25%	-70.91%
% of Gross Profit
Depreciation & Amortization	$2.070K	$2.070K	$2.070K
YoY Change	1378.57%	-27.87%
% of Gross Profit
Operating Expenses	$3.188M	$3.830M	$3.059M
YoY Change	-21.55%	-13.02%	-36.8%
Operating Profit	-$3.188M	-$3.830M	-$3.059M
YoY Change	-21.55%	-13.02%
Interest Expense	$3.340K	$6.930K	$5.120K
YoY Change	16.78%	487.29%
% of Operating Profit
Other Income/Expense, Net	$78.34K	-$17.07K	$146.0K
YoY Change	-130.47%	-54.12%	1360.0%
Pretax Income	-$3.109M	-$3.848M	-$2.908M
YoY Change	-27.99%	-13.36%	-39.8%
Income Tax
% Of Pretax Income
Net Earnings	-$3.109M	-$3.848M	-$2.908M
YoY Change	-27.99%	-13.36%	-39.84%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.12	-$0.16	-$0.13
Diluted Earnings Per Share	-$0.12	-$0.16	-$125.6K
COMMON SHARES
Basic Shares Outstanding	25.85M shares	24.32M shares	23.15M shares
Diluted Shares Outstanding	25.72M shares	24.32M shares	23.15M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.753M	$9.157M	$12.69M
YoY Change	-19.88%	75.76%	124.99%
Cash & Equivalents	$5.753M	$9.157M	$12.69M
Short-Term Investments
Other Short-Term Assets	$1.021M	$783.0K	$275.8K
YoY Change	26.73%	105.99%	-47.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.773M	$9.940M	$12.96M
YoY Change	-15.18%	77.81%	110.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.36K	$54.29K	$289.8K
YoY Change	-83.67%	-83.69%	-6.52%
Goodwill	$249.0K	$249.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$968.4K	$983.7K	$998.7K
YoY Change	-60.64%	-60.22%	-59.4%
TOTAL ASSETS
Total Short-Term Assets	$6.773M	$9.940M	$12.96M
Total Long-Term Assets	$968.4K	$983.7K	$998.7K
Total Assets	$7.742M	$10.92M	$13.96M
YoY Change	-25.89%	35.48%	61.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$278.2K	$617.8K	$415.1K
YoY Change	50.22%	29.4%	-35.14%
Accrued Expenses	$955.4K	$1.009M	$1.746M
YoY Change	-46.1%	-41.87%	26.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.327M	$1.867M	$2.171M
YoY Change	-32.22%	-15.65%	6.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$982.3K	$1.072M	$1.062M
YoY Change	-23.75%	5.0%	9.46%
Total Long-Term Liabilities	$982.3K	$1.072M	$1.062M
YoY Change	-23.75%	5.0%	9.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.327M	$1.867M	$2.171M
Total Long-Term Liabilities	$982.3K	$1.072M	$1.062M
Total Liabilities	$2.333M	$2.962M	$3.256M
YoY Change	-28.14%	-8.41%	8.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.81M	-$57.70M
YoY Change
Common Stock	$26.85K	$25.85K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.409M	$7.961M	$10.71M
YoY Change
Total Liabilities & Shareholders Equity	$7.742M	$10.92M	$13.96M
YoY Change	-25.89%	35.48%	61.8%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.109M	-$3.848M	-$2.908M
YoY Change	-27.99%	-13.36%	-39.84%
Depreciation, Depletion And Amortization	$2.070K	$2.070K	$2.070K
YoY Change	1378.57%	-27.87%
Cash From Operating Activities	-$3.404M	-$3.534M	-$2.497M
YoY Change	-3.56%	10.22%	-12.09%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.870K	9.124M
YoY Change	-100.0%	-99.93%	123.62%
NET CHANGE
Cash From Operating Activities	-3.404M	-3.534M	-2.497M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	0.000	1.870K	9.124M
Net Change In Cash	-3.404M	-3.533M	$0.00
YoY Change	-272.76%	719.08%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.404M	-$3.534M	-$2.497M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$3.404M	-$3.534M	-$2.497M
YoY Change	-3.56%	11.42%	-11.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	ADIL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38323
	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1180 Seminole Trail
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 495
	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22901
	dei	City Area Code CityAreaCode	(434)
	dei	Local Phone Number LocalPhoneNumber	422-9800
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25853962	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9156635	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	588931	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	9931	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	194054	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	389501	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9939620	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6461605	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54287	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58149	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4759	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5041	usd
CY2022Q2	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2021Q4	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	220660	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246209	usd
CY2022Q2	us-gaap	Goodwill Goodwill	248971	usd
CY2021Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2022Q2	us-gaap	Assets Assets	10923297	usd
CY2021Q4	us-gaap	Assets Assets	7474975	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	617778	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	286192	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1009042	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	175000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	53136	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	49585	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11860	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9683	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1866816	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2722390	usd
CY2022Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	892000	usd
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1014000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	179702	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207375	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23399	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23399	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2961917	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3967164	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25853962	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25853962	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20946712	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20946712	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	25854	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20947	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65634012	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54429979	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57698486	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50943115	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7961380	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10923297	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7474975	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1200127	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2319049	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1796468	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4370672	usd
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2630335	usd
CY2021Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2084676	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5092948	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4873387	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	3830462	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	4403725	usd
	us-gaap	Operating Expenses OperatingExpenses	6889416	usd
	us-gaap	Operating Expenses OperatingExpenses	9244059	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3830462	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4403725	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6889416	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9244059	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6930	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1181	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12045	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1476	usd
CY2022Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-24000	usd
CY2021Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-67478	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	122000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-61203	usd
CY2021Q2	us-gaap	Other Income OtherIncome	29088	usd
	us-gaap	Other Income OtherIncome	29088	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17070	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-37209	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	134045	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30639	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3847532	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4440934	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6755371	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9274698	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3847532	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4440934	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6755371	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9274698	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24316031	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17588840	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23330652	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16854425	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	567189	usd
CY2022Q1	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	416423	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2907839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10707325	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	625816	usd
CY2022Q2	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	473906	usd
CY2022Q2	adil	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1865	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3847532	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7961380	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3986066	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	473787	usd
CY2021Q1	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	850900	usd
CY2021Q1	adil	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1425000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14500	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1060150	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2641003	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4833764	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	5617642	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	568295	usd
CY2021Q2	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	275000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2809000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4440934	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	4829003	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6755371	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9274698	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2083334	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2167982	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	29088	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	3862	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2593	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6954	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	282	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	282	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	25549	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	23561	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	122000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-61203	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	579000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195447	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-354615	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1367888	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	833085	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	175000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	333763	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-172235	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-24122	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-21010	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6031144	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6046756	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64605	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-30589	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34016	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9123741	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5450003	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1425000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9125606	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6889503	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3094462	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	808731	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4401114	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9156635	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5209845	usd
	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses	1060150	usd
	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares	732287	usd
CY2022Q2	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.44	pure
CY2022Q2	adil	Accumulated Deficit AccumulatedDeficit	-57700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant items subject to such estimates and assumptions include the valuation of stock-based compensation, accruals associated with third party providers supporting clinical trials, estimated fair values of long-lived assets used to record impairment charges related to intangible assets, acquired in-process research and development (“IPR&D”) and goodwill, allocation of purchase price in business acquisitions, measurement of contingent liabilities, and income tax asset realization. In particular, the recognition of clinical trial costs is dependent on the Company’s own judgement, as well as the judgment of our contractors and subcontractors in their reporting of information to us.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	12095870	shares
	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	7884936	shares
	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	4181977	shares
	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	3670866	shares
	adil	Unvested Restricted Stock Awards UnvestedRestrictedStockAwards	215279	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16493126	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11555802	shares
	adil	Schedule Of Probabilityweighted Cash Flows Were Discounted Using A Weighted Average Cost Of Capital Tabletext Block ScheduleOfProbabilityweightedCashFlowsWereDiscountedUsingAWeightedAverageCostOfCapitalTabletextBlock	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance, December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,014,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Total gains recognized</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">122,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(892,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1014000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	122000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	892000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	455000	usd
CY2021Q1	us-gaap	Business Acquisitions Purchase Price Allocation Year Of Acquisition Net Effect On Income BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionNetEffectOnIncome	2142437	usd
CY2021Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	455000	usd
CY2021Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	248971	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	455000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	248971	usd
CY2021Q1	adil	Net Loss NetLoss	107000	shares
CY2022Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	29088	usd
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.01	pure
	adil	Paycheck Protection Program Term PaycheckProtectionProgramTerm	P2Y
CY2021Q2	us-gaap	Other Notes Payable OtherNotesPayable	29088	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	455000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	248971	usd
CY2021Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2022Q2	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	187160	usd
CY2021Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	1826479	usd
CY2022Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	498628	usd
CY2021Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	520795	usd
CY2022Q2	adil	Manufacturing Expenses ManufacturingExpenses	-299611	usd
CY2022Q2	adil	Legal And Consulting Services LegalAndConsultingServices	23643	usd
CY2021Q4	adil	Legal And Consulting Services LegalAndConsultingServices	29656	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1009042	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2020Q4	adil	Membership Interest Description MembershipInterestDescription	Mr. Stilley owned approximately 28.7% of the membership interest of Purnovate and Mr. Newman controlled two entities that, together, own less than 1% of the membership interests of Purnovate. As a result of the foregoing, the Company formed a Special Committee of independent members of its Board of Directors to review and negotiate the acquisition terms.
CY2021Q1	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	the Company entered into Securities Purchase Agreements (the “March 2021 SPAs”) with each of Bespoke, three entities controlled by Mr. Newman, and Keystone Capital Partners, LLC (“Keystone”), pursuant to which: (i) Bespoke Growth Partners, Inc. (“Bespoke”) a company controlled by Mark Peikin, the Company’s Chief Strategy Officer who is not an executive officer, agreed to purchase an aggregate of 336,667 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,010,001; (ii) Mr. Newman agreed to purchase an aggregate of 30,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $90,000; and (iii) Keystone agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,000,002. During the year ended December 31, 2021, the Company issued an aggregate of 700,001 shares of common stock to such individuals for total proceeds of $2,100,003. The shares sold pursuant to the March 2021 SPAs were registered pursuant to a registration statement on Form S-3 that was filed with the SEC on April 20, 2021 and declared effective on May 26, 2021.
CY2021Q3	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	the Company entered into Securities Purchase Agreements, dated July 6, 2021 (the “June 2021 SPAs”), with three pre-existing investors for an aggregate investment of $5,000,004 in consideration of the purchase by such investors of an aggregate of 1,666,667 shares of the Company’s common stock at a purchase price of $3.00 per share. June 2021 SPAs were entered with each of Bespoke , Keystone, and Richard Gilliam, a private investor (“Gilliam”) (collectively, the “Investors,” and each an “Investor”), pursuant to which: (i) Bespoke agreed to purchase an aggregate of 833,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $2,500,002; (ii) Keystone agreed to purchase an aggregate of 500,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,500,000; and (iii) Gilliam agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for gross proceeds of $1,000,002.
CY2022Q1	adil	Common Stock Issuances CommonStockIssuances	On February 10, 2022, the Company, entered into a securities purchase agreement with an accredited institutional investor (“the Investor”) providing for the issuance of (i) 2,322,250 shares of the Company’s common stock, par value $0.001, (ii) pre-funded warrants to purchase up to 1,865,000 shares of common stock with an exercise price of $0.001 per share, which Pre-Funded Warrants are to be issued in lieu of shares of common stock to ensure that the Investor does not exceed certain beneficial ownership limitations, and (iii) warrants, with a term of five years and six months from the date of issuance, to purchase an aggregate of up to 3,977,888 shares of common stock at an exercise price of $2.52 per share.
CY2022Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	1865	usd
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1865000	shares
CY2022Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	270000	shares
CY2022Q2	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	418350	usd
	adil	Stock Issued During Period Shares Other1 StockIssuedDuringPeriodSharesOther1	470000	shares
	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	818350	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	the Company issued an employee 250,000 shares common stock as a bonus on salary. The shares are subject to repurchase by the Company on termination of the employee, the shares no longer being liable to repurchase (“vesting”) on the following schedule: 1/24 of 166,667 shares vesting on the date of issue and the first of each of the next twenty-three subsequent months, and 83,333 shares vesting on the third anniversary of the date of issue. On June 30, 2022, 34,721 shares were vested and 215,279 shares remained subject to repurchase.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3585310	shares
	adil	Weighted Average Remaining Term Years Balances WeightedAverageRemainingTermYearsBalances	P7Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	596667	shares
	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	1.95
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.59
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4181977	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M13D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.53
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2722514	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Non Vested Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingNonVestedContractualTerm1	P7Y1M6D
CY2022Q2	adil	Share Based Payment Award Optons Exercises In Period Vested Weighted Average Exercise Price ShareBasedPaymentAwardOptonsExercisesInPeriodVestedWeightedAverageExercisePrice	2.68
	adil	Share Based Compnasation Arrangement By Weighted Average Fair Value At Issue Outstanding Vested And Exercisablein Shares ShareBasedCompnasationArrangementByWeightedAverageFairValueAtIssueOutstandingVestedAndExercisableinShares	2.02
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3850	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	596667	usd
	adil	Weighted Averages Fair Value WeightedAveragesFairValue	950601	usd
	adil	Weighted Average Fair Value Per Share WeightedAverageFairValuePerShare	1.59
	adil	Unrecognized Compensation Expense UnrecognizedCompensationExpense	2747791	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y10M17D
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	52438	usd
CY2021Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	77177	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	128828	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	143809	usd
CY2022Q2	adil	Total Research And Development Expenses TotalResearchAndDevelopmentExpenses	52438	usd
CY2021Q2	adil	Total Research And Development Expenses TotalResearchAndDevelopmentExpenses	77177	usd
	adil	Total Research And Development Expenses TotalResearchAndDevelopmentExpenses	128828	usd
	adil	Total Research And Development Expenses TotalResearchAndDevelopmentExpenses	143809	usd
CY2022Q2	adil	General And Administrative Options And Warrants Expense GeneralAndAdministrativeOptionsAndWarrantsExpense	573378	usd
CY2021Q2	adil	General And Administrative Options And Warrants Expense GeneralAndAdministrativeOptionsAndWarrantsExpense	491118	usd
	adil	General And Administrative Options And Warrants Expense GeneralAndAdministrativeOptionsAndWarrantsExpense	1064177	usd
	adil	General And Administrative Options And Warrants Expense GeneralAndAdministrativeOptionsAndWarrantsExpense	898273	usd
CY2022Q2	adil	Stock Issued Granted For Performance Bonus Plan Cancellation StockIssuedGrantedForPerformanceBonusPlanCancellation	473906	usd
CY2021Q2	adil	Stock Issued Granted For Performance Bonus Plan Cancellation StockIssuedGrantedForPerformanceBonusPlanCancellation	275000	usd
	adil	Stock Issued Granted For Performance Bonus Plan Cancellation StockIssuedGrantedForPerformanceBonusPlanCancellation	890329	usd
	adil	Stock Issued Granted For Performance Bonus Plan Cancellation StockIssuedGrantedForPerformanceBonusPlanCancellation	1125900	usd
CY2022Q2	adil	Total General And Administrative Expenses TotalGeneralAndAdministrativeExpenses	1047284	usd
CY2021Q2	adil	Total General And Administrative Expenses TotalGeneralAndAdministrativeExpenses	766118	usd
	adil	Total General And Administrative Expenses TotalGeneralAndAdministrativeExpenses	1954506	usd
	adil	Total General And Administrative Expenses TotalGeneralAndAdministrativeExpenses	2024173	usd
CY2022Q2	adil	Stockbased Compensation Expense StockbasedCompensationExpense	1099722	usd
CY2021Q2	adil	Stockbased Compensation Expense StockbasedCompensationExpense	843295	usd
	adil	Stockbased Compensation Expense StockbasedCompensationExpense	2083334	usd
	adil	Stockbased Compensation Expense StockbasedCompensationExpense	2167982	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7990271	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y7M17D
CY2021Q4	adil	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisesPrice	4.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	6042888	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.74
	adil	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	1865000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.001
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12168159	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y6M14D
CY2022Q2	adil	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisesPrice	4.03
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.01
	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
CY2022Q2	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
	us-gaap	Royalty Expense RoyaltyExpense	20000	usd
CY2022Q2	adil	Accrued License Royalty Expense AccruedLicenseRoyaltyExpense	155000	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	175000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2018Q4	adil	Master Services Agreement Description MasterServicesAgreementDescription	The MSA has a term of five years, automatically renewed for two-year periods, unless either party gives written notice of a decision not to renew the agreement six months prior to automatic renewal.
CY2018Q4	adil	Service Agreement Description ServiceAgreementDescription	On November 16, 2018, the Company and Crown entered into Service Agreement 1 under the MSA for a 24 week, multi-centered, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study of AD04 for fees, as amended, of $3,319,734 (€3,168,895 converted to dollars at the Euro/US Dollar exchange rate of 1.0476 as of June 30, 2022), payable upon attainment of certain milestones. On March 22, 2022, the Company acknowledged the occurrence of the milestone event of 90% of trial case report forms having been monitored, and made a payment of $148,875. On May 13, 2022, the Company acknowledged the milestone event of the last patient having made the last clinical visit and made a payment of $146,765, and on June 30, 2022 the Company acknowledged the additional milestone event of the trial database being locked at which time it recognized a payable of $137,375.
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	454034	usd
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	410000	eur
	us-gaap	Other Noncash Income OtherNoncashIncome	275516	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	80206	usd
CY2021Q1	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.09	pure
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	21480	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	18942	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	40856	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	33859	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	21480	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	18942	usd
	us-gaap	Lease Cost LeaseCost	40856	usd
	us-gaap	Lease Cost LeaseCost	33859	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	34988	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	33859	usd
	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	5868	usd
	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	294294	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246209	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	246209	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	49585	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	207375	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	256960	usd
	adil	Advance Payment AdvancePayment	579000	usd
CY2022Q2	adil	Future Cash FutureCash	1500000	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M29D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	34990	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	72687	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	75231	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	77864	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6508	usd
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	267280	usd
CY2022Q2	adil	Operating Leases Future Minimum Payments Less Effects Of Discounting OperatingLeasesFutureMinimumPaymentsLessEffectsOfDiscounting	-34442	usd
CY2022Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	232838	usd
CY2020Q1	adil	Lease Commitments Related Party Description LeaseCommitmentsRelatedPartyDescription	the Company entered into a sublease with Purnovate, LLC, a private company in which the Company’s CEO had a 28.7% equity interest, for the lease of three offices at 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901. The lease had a term of two years, and the monthly rent was $1,400. During both the three and six months ended June 30, 2021, the rent expense associated with this lease was $1,400. On acquisition of Purnovate, the sublease was terminated and the Company assumed the obligations of Purnovate’s lease.
CY2019Q1	adil	Consulting Agreement Description ConsultingAgreementDescription	the Company entered into a consulting agreement (the “Consulting Agreement”) with Dr. Bankole A. Johnson, who at the time of the agreement was serving as the Chairman of the Board of Directors, for his service as Chief Medical Officer of the Company. The Consulting Agreement has a term of three years, unless terminated by mutual consent or by the Company for cause, which term was extended on March 22, 2022 for an additional three years commencing as of March 24, 2022. Dr. Johnson resigned as Chairman of the Board of Directors at the time of execution of the consulting agreement. Under the terms of the Consulting Agreement, Dr. Johnson’s annual fee of $375,000 per year is paid twice per month. The Consulting Agreement had an expiration date of March 31, 2022, which was extended on March 22, 2022 for an additional three years commencing as of March 24, 2022. The Company recognized $93,750 and $187,500 in compensation expense in the both the three and six months ended June 30, 2022 and 2021, respectively, as a result of this agreement.
CY2019Q3	adil	Master Services Agreement Description MasterServicesAgreementDescription	It is anticipated that the compensation to be paid to PEPCO for services under the PEPCO MSA will total approximately $300,000.
	us-gaap	Long Term Purchase Commitment Specified Form Of Payment LongTermPurchaseCommitmentSpecifiedFormOfPayment	$1,409,000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses		usd
	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares		usd
	adil	Unvested Restricted Stock Awards UnvestedRestrictedStockAwards		shares
CY2021Q4	adil	Manufacturing Expenses ManufacturingExpenses		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-22-047638-index-headers.html	Edgar Link	pending
0001213900-22-047638-index.html	Edgar Link	pending
0001213900-22-047638.txt	Edgar Link	pending
0001213900-22-047638-xbrl.zip	Edgar Link	pending
adil-20220630.xsd	Edgar Link	pending
f10q0622ex31-1_adialpharm.htm	Edgar Link	pending
f10q0622ex31-2_adialpharm.htm	Edgar Link	pending
f10q0622ex32-1_adialpharm.htm	Edgar Link	pending
f10q0622ex32-2_adialpharm.htm	Edgar Link	pending
f10q0622_adialpharm.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
adil-20220630_cal.xml	Edgar Link	unprocessable
adil-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
adil-20220630_pre.xml	Edgar Link	unprocessable
adil-20220630_lab.xml	Edgar Link	unprocessable
f10q0622_adialpharm_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

2022 Q3 Form 10-Q Financial Statement

#000121390022047638 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL ADIAL PHARMACEUTICALS, INC. Stock $adil

2022 Q3 Form 10-Q Financial Statement

#000121390022047638 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil